AUTHORS
Samuel R. Taylor, MD, PhD, Kimon Argyropoulos, MD, PhD2, Meghan C. Thompson, MD3, Chloe Park4, Charlotte Wishnack5, Zoe Pierce6, Kenton Wu7, Catherine Snopkowski8, Ning Fan9, Ronan Chaligne, PhD10, Eric Rosiek, MS11, Omar Abdel-Wahab, MD12, Joseph M. Chan, MD, PhD13, Susan DeWolf, MD14
AFFILIATIONS
1 Memorial Sloan Kettering Cancer Center, New York, United States
2 Memorial Sloan Kettering Cancer Center, New York, United States
3 Memorial Sloan Kettering Cancer Center, New York, United States
4 , New York, NY, United States
5 Memorial Sloan Kettering Cancer Center, New York, United States
6 Memorial Sloan Kettering Cancer Center, New York, United States
7 Memorial Sloan Kettering Cancer Center, New York, United States
8 Memorial Sloan Kettering Cancer Center, New York, United States
9 Memorial Sloan Kettering Cancer Center, New York, United States
10 Memorial Sloan Kettering Cancer Center, New York, United States
11 , New York, NY, United States
12 , New York, NY, United States
13 , New York, NY, United States
14 Memorial Sloan Kettering Cancer Center, New York, United States
ABSTRACT
Richter transformation (RT) is an aggressive large cell lymphoma arising from CLL with a median survival of ~1 year. RT develops along a proliferative continuum that includes an intermediate accelerated CLL stage (aCLL), and transforming clones may persist within the bulk CLL population years before clinical transformation. However, the in situ transcriptional programs and microenvironmental interactions that drive precursor states to overt RT are poorly understood. Here, we applied clonally-resolved spatial transcriptomics to identify ancestral and transformed CLL cells in situ and map their local immune ecosystems across longitudinal biopsies from 14 patients spanning CLL, aCLL, and RT. We discovered a recurrent metabolic adaptation program in clonal B cells that concentrates in proliferative CLL niches and intensifies from CLL to aCLL to RT. These niches showed stage-specific immune remodeling, with inflammatory macrophages and proliferating T cells enriched in aCLL followed by CD8 T-cell exhaustion after transformation, suggesting that these niches may mark impending immune dysfunction and transformation.
Our retrospective cohort included 39 biopsies (30 lymph node, 9 bone marrow) from 14 patients with RT, including 10 that also had paired pre-RT tissue. We analyzed these using single-cell spatial transcriptomics via the Xenium in situ platform and annotated 11.5 million cellular transcriptomes across 35 cell states. To distinguish ancestral CLL cells from transformed subclones within the same sample, we used clinical next-generation sequencing (NGS) to design probes for patient-specific BCR clonotypes and for mutations acquired at RT. BCR probes labeled the CLL lineage in up to 83% of B cells and closely mirrored clonal burden measured by clinical ClonoSEQ sequencing (r=0.99, p=0.006, n=4), while RT-mutation probes correlated well with NGS VAF. Both probe types showed high specificity, with only 0.45 false-positive cells per 1,000 cells in control tissue lacking the target BCR or mutant transcript.
To define the spatial niches of CLL cells, we used optimal transport-based spatial analysis to identify 24 recurrent niches shared across patients and tissue types. RT cells preferentially localized to proliferative niches where clonal B cells expressed a metabolic program spanning glycolysis/hypoxia adaptation (LDHA, PKM, ENO1), mitochondrial metabolism and metabolite flux (IDH2, VDAC1), amino acid transport/nutrient uptake (SLC7A5), and redox homeostasis (AKR1B1). Composite expression of this program increased with progression from CLL to aCLL to RT across the cohort and within paired pre/post-transformation samples. IDH2 and AKR1B1 showed the strongest enrichment in RT overall, ranking among the top five differentially expressed genes (padj<4×10-13). AKR1B1 was the strongest metabolic feature enriched in aCLL versus CLL, whereas SLC7A5 showed the greatest induction from aCLL to RT, highlighting stage-specific metabolic vulnerabilities. Notably, AKR1B1 and SLC7A5 encode pharmacologically tractable metabolic proteins implicated in cancer progression, and SLC7A5/LAT1 inhibitors are in clinical development for other malignancies.
Immune remodeling accompanied tumor metabolic rewiring within the proliferative niches. Niche-resident macrophages acquired an IFN-γ/STAT1 inflammatory program, marked by STAT1/IRF1 activation, CXCL9/10/11 induction, and reduced CD163, that emerged at aCLL and strengthened at RT. In parallel, Naïve and memory T cells were depleted with CLL progression, while proliferative CD8 T cells expanded at aCLL, suggesting disease-related activation. Following RT, niche-resident CD8 T cells acquired a CXCL13+TOX+ exhaustion-like phenotype with diminished expression of cytotoxic markers.
Together, these data establish a clone-resolved spatial framework for defining precursor states of Richter transformation. Using this framework, we find that CLL cells undergo metabolic reprograming within proliferative niches and that this precedes overt RT and is coupled to progressive immune remodeling. These findings nominate tumor metabolic adaptation and the co-evolving immune microenvironment as complementary vulnerabilities for early intervention prior to clinical transformation.
DISCLOSURES
Samuel R. Taylor, MD, PhD: No relevant conflicts of interest to declare.